Amphastar Pharmaceuticals (AMPH) Price to Sales (2014 - 2026)

Amphastar Pharmaceuticals has reported Price to Sales for 13 years, with the latest figure at 4.67 in Q2 2026.

• On a quarterly basis, Price to Sales fell 23.74% year-over-year to 4.67 in Q2 2026; TTM through Jun 2026 was 1.18, a 20.4% decrease from a year earlier, with the FY2025 full-year figure at 1.7, down 29.7% from the prior year.
• Price to Sales was 4.67 for Q2 2026 at Amphastar Pharmaceuticals, down from 5.11 in the prior quarter.
• The five-year high for Price to Sales was 19.25 in Q2 2023, with the low at 4.67 in Q2 2026.
• Average Price to Sales over 5 years is 10.71, with a median of 11.05 recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Price to Sales surged 71.35% in 2022, then sank 47.56% in 2025.
• Over 5 years, Price to Sales stood at 9.98 in 2022, then jumped by 67.19% to 16.69 in 2023, then plunged by 43.22% to 9.48 in 2024, then declined by 29.57% to 6.68 in 2025, then tumbled by 30.09% to 4.67 in 2026.
• The last three Price to Sales figures came in at 4.67 (Q2 2026), 5.11 (Q1 2026), and 6.68 (Q4 2025), per Business Quant data.